Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.62 - $18.42 $526,320 - $663,120
36,000 New
36,000 $585,000
Q2 2023

Aug 14, 2023

BUY
$17.8 - $25.65 $5,998 - $8,644
337 Added 2.93%
11,837 $283,000
Q1 2023

May 15, 2023

BUY
$16.32 - $20.92 $187,680 - $240,580
11,500 New
11,500 $216,000
Q2 2022

Aug 15, 2022

BUY
$13.01 - $27.22 $542,464 - $1.13 Million
41,696 New
41,696 $587,000
Q1 2020

May 15, 2020

SELL
$31.65 - $46.87 $186,735 - $276,533
-5,900 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$36.21 - $51.4 $213,639 - $303,260
5,900 New
5,900 $252,000
Q4 2017

Feb 12, 2018

SELL
$26.84 - $39.14 $686,674 - $1 Million
-25,584 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$29.49 - $38.37 $754,472 - $981,658
25,584
25,584 $964,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.